<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154864">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02083991</url>
  </required_header>
  <id_info>
    <org_study_id>2012-000451-13</org_study_id>
    <nct_id>NCT02083991</nct_id>
  </id_info>
  <brief_title>Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation</brief_title>
  <acronym>SAILOR</acronym>
  <official_title>A Controlled Randomized, Open-label, Multi-centre Study Evaluating if a Steroid-free Immunosuppressive Protocol, Based ATG-induction, Low Tacrolimus-dose and Therapeutic Drug Monitoring of Mycophenolate Mofetil, Reduces the Incidence of New Onset Diabetes After Transplantations, in Comparison With Standard Steroid-based Protocol With Low-dose Tacrolimus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Balancing immunosuppressive treatment in organ transplantation in order to achieve effective
      prevention of rejection on one side and avoidance of negative side effects on the other side
      is a major challenge, leading to developing different immunosuppressive protocols.
      Cornerstones of immunosuppressive treatment such as Corticosteroids (CS) and Calcineurin
      Inhibitors (CNI) are known to cause an increased incidence of diabetes, cardiovascular
      morbidity, nephrotoxicity and malignancies.

      The investigators believe that both avoidance of CS and minimization of CNI, while using
      Anti-ThymocyteGlobuline(ATG) induction (instead of interleucin-2 receptor blockers) and
      mycofenolate mofetil(MMF) therapeutic drug monitoring is going to reduce negative side
      effects, without increased rejection frequency in renal transplanted patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cumulative incidence of New Onset of Diabetes After Transplantation(NODAT)</measure>
    <time_frame>12 month after transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of NODAT</measure>
    <time_frame>3, 6, 24 month after transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite measure</measure>
    <time_frame>12, 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Freedom from acute rejection, graft and patient survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>12, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluated by measured glomerular filtration rate (mGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute rejection and chronic changes</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysed by protocol biopsies, evaluated by the Banff system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypertension</measure>
    <time_frame>3, 12, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Standardized measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antihypertensive treatment</measure>
    <time_frame>3, 12, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number and type of antihypertensive drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid lowering drugs</measure>
    <time_frame>12, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number and type of lipid lowering drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibody-mediated rejection</measure>
    <time_frame>12, 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysed by biopsies, evaluated by the Banff system, and by donor-specific HLA antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative frequency of cardiovascular complications and events.</measure>
    <time_frame>10 days, 3, 12, 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Collecting Adverse Events (AE) reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative frequency of malignancy.</measure>
    <time_frame>6, 12, 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Collecting AE reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative frequency of infections</measure>
    <time_frame>10 days, 3, 6, 12, 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Collecting AE reports</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Steroid-free low TAC-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy: Thymoglobulin i.v. 2,5 mg/kg day 0 and 1, preceded by methylprednisolone i.v. 250 mg day 0 and 50 mg day 1.
Maintenance therapy: Advagraf(TAC) 0,2 mg/kg p.o. started day1 (target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml; MMF 1g x 2 p.o. (target Area Under Curve, AUC 40-60 mg.h/L); No steroids p.o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard low-TAC arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy: Simulect i.v. 20 mg day 0 and 4; Steroids i.v. according to local practice.
Maintenance therapy: Advagraf(TAC) p.o. 0,2 mg/(target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml); MMF 1g x 2 p.o. (target AUC 40-60 mg.h/L); Steroids p.o. according to hospital practice (but not less than 5mg daily after 6 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid-free low TAC-arm: Thymoglobulin  Standard low-TAC arm: Simulect, prednisolon</intervention_name>
    <arm_group_label>Steroid-free low TAC-arm</arm_group_label>
    <arm_group_label>Standard low-TAC arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First or second single kidney (cadaveric or living donors) transplant recipients.

          -  Considered for a standard immunosuppressive protocol.

          -  Must be capable of giving written informed connect for participation in the study for
             24 months.

        Exclusion Criteria:

          -  Diabetes mellitus or plasma glucose &gt;11,1 at admission.

          -  Receiving steroids at the time of transplantation or likely to need steroids after
             transplantation.

          -  Multiorgan transplants and/or previously transplanted with any other organ than
             kidney.

          -  Panel reacting antibodies(PRA) &gt;25% in most recent test or considered to be of high
             risk for rejection which requires an  enhanced immunosuppression.

          -  Renal transplants from HLA-identical sibling.

          -  Hypersensitivity to, or disability to take immunosuppressive drugs.

          -  Blood group(ABO)-incompatible transplants.

          -  Unlikely to comply with the study requirements.

          -  Transplant from donor positive for HIV, HBsAg, Hepatitis C.

          -  Female of childbearing potential planing/being pregnant or unwilling to use
             contraception.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Lindnér, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transplant Center, Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Per Lindnér, MD</last_name>
    <phone>+46705548400</phone>
    <email>per.lindner@vgregion.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Transplant Institute, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Lindnér, MD</last_name>
      <phone>+46705548400</phone>
      <email>per.lindner@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Jana Ekberg</last_name>
      <phone>+46313421000</phone>
      <email>jana.ekberg@vgregion.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>March 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NODAT</keyword>
  <keyword>Renal transplantation</keyword>
  <keyword>Corticosteroids avoidance</keyword>
  <keyword>CNI minimization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
